BONYF NV Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India

Knokke-Heist, Belgium, June 3, 2025 — BONYF NV, a leader in dental consumer goods, professional dental consumables, and dermatological solutions, has announced a significant strategic partnership with Group Pharmaceuticals, a leading Indian oral health company. Group Pharmaceuticals has acquired a 13.5% stake in BONYF NV, marking a strong commitment to a long-term strategic partnership aimed at accelerating BONYF’s growth in the Indian market.

This collaboration is a major step forward in BONYF’s global expansion strategy. Group Pharmaceuticals, a prominent player in India’s oral healthcare sector, has a field force that directly reaches over 100,000 dentists every month. This extensive market access provides a powerful platform for promoting BONYF’s high-performance oral care products to dental professionals and their patients across India.

As part of the partnership, Group Pharmaceuticals will begin local production of selected BONYF-licensed products in India. This move is expected to enhance the distribution and availability of BONYF’s products in the Indian market, ensuring cost-effective solutions for consumers.

BONYF NV, listed on the NYSE Euronext Paris with a close price of 15.8 EUR as of May 29, 2025, has seen its shares fluctuate between a 52-week high of 19.5 EUR on February 24, 2025, and a 52-week low of 14.2 EUR on October 29, 2024. The partnership with Group Pharmaceuticals is anticipated to positively impact BONYF’s market position and financial performance as it capitalizes on the growing demand for oral healthcare products in India.

This strategic stakeholder relationship underscores BONYF’s commitment to expanding its global footprint and leveraging local expertise to drive growth in key international markets.